Hidradenitis Suppurativa - Pipeline Review, H1 2018

  • ID: 4457545
  • Report
  • 99 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • Coherus BioSciences Inc
  • Fresenius SE & Co KGaA
  • Immunwork Inc
  • InflaRx NV
  • MORE
Hidradenitis Suppurativa - Pipeline Review, H1 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2018, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5, 1, 2 and 2 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Celgene Corp
  • Coherus BioSciences Inc
  • Fresenius SE & Co KGaA
  • Immunwork Inc
  • InflaRx NV
  • MORE
Introduction

Hidradenitis Suppurativa - Overview

Hidradenitis Suppurativa - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hidradenitis Suppurativa - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hidradenitis Suppurativa - Companies Involved in Therapeutics Development

AbbVie Inc

Celgene Corp

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Immunwork Inc

InflaRx NV

Innovation Pharmaceuticals Inc

Novartis AG

UCB SA

XBiotech Inc

Hidradenitis Suppurativa - Drug Profiles

adalimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimekizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJM-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Xilonix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hidradenitis Suppurativa - Dormant Projects

Hidradenitis Suppurativa - Discontinued Products

Hidradenitis Suppurativa - Product Development Milestones

Featured News & Press Releases

Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology

Oct 31, 2017: Innovation Pharma Provides Update on Brilacidin

Oct 03, 2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board

Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa

Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Jun 12, 2017: AbbVie's Humira accepted for use in NHS Scotland

Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application

Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa

Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa

Nov 14, 2016: AbbVie's HUMIRA (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease

Sep 26, 2016: AbbVie To present New Data on HUMIRA (adalimumab) at the 25th European Academy of Dermatology and Venereology Congress

Aug 03, 2016: Clinical trial results support adalimumab treatment for painful skin condition

May 09, 2016: Scottish Medicines Consortium (SMC) accepts Humira (adalimumab) as the first approved treatment for the painful, chronic skin condition hidradenitis suppurativa for patients in Scotland

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Hidradenitis Suppurativa - Pipeline by AbbVie Inc, H1

Hidradenitis Suppurativa - Pipeline by Celgene Corp, H1

Hidradenitis Suppurativa - Pipeline by Coherus BioSciences Inc, H1

Hidradenitis Suppurativa - Pipeline by Fresenius SE & Co KGaA, H1

Hidradenitis Suppurativa - Pipeline by Immunwork Inc, H1

Hidradenitis Suppurativa - Pipeline by InflaRx NV, H1

Hidradenitis Suppurativa - Pipeline by Innovation Pharmaceuticals Inc, H1

Hidradenitis Suppurativa - Pipeline by Novartis AG, H1

Hidradenitis Suppurativa - Pipeline by UCB SA, H1

Hidradenitis Suppurativa - Pipeline by XBiotech Inc, H1

Hidradenitis Suppurativa - Dormant Projects, H1

Hidradenitis Suppurativa - Discontinued Products, H1

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Celgene Corp
  • Coherus BioSciences Inc
  • Fresenius SE & Co KGaA
  • Immunwork Inc
  • InflaRx NV
  • Innovation Pharmaceuticals Inc
  • Novartis AG
  • UCB SA
  • XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll